

Patents Granted

We are pleased to announce that the Japanese Patent Office has recognized the novelty and usefulness of the anti-CD71 antibody-nucleic acid conjugate and granted a patent for our nucleic acid delivery technology, as follows.

- Patent Number: JP7138965B2.
- Patent application date: 21 December 2020.
- Patent date: 20 September 2022.
- Patentee: GenAhead Bio Inc.

The patent will be granted for compositions of nucleic acids conjugated with anti-CD71 antibodies and used for delivery to target organs. The patent will enable the delivery of nucleic acids to organs other than the liver, which has traditionally been the primary target organ for nucleic acids and will enable the delivery of effective therapeutics to patients with immune disorders.

GenAhead Bio is a bio venture with proprietary genome editing and nucleic acid delivery technologies based on extensive experience. In the area of genome editing, GenAhead Bio produces disease model cells for difficult single nucleotide polymorphism (SNP) replacements at high rates and in a short time and provides them to pharmaceutical companies and bio-ventures. GenAhead Bio also has technologies for skeletal muscle and cardiac nucleic acid delivery. In addition to contract services, licensing, and collaborative research and development are available in both areas.

<https://en.genaheadbio.co.jp/>

For further information, please contact us by e-mail: info@genaheadbio.com